Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:CVSI NASDAQ:EVOK OTCMKTS:GLUC NASDAQ:GTBP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVSICV Sciences$0.04+1.7%$0.03$0.02▼$0.06$6.65M0.61145,055 shs50,681 shsEVOKEvoke Pharma$4.69+29.2%$3.65$1.94▼$12.32$5.42M-0.047.26 million shs350,411 shsGLUCGlucose Health$0.11+0.5%$0.10$0.08▼$0.38$1.84M1.796,579 shs400 shsGTBPGT Biopharma$1.81-2.7%$2.62$1.72▼$4.10$6.09M1.33105,373 shs38,748 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVSICV Sciences+1.67%+3.10%-3.17%+35.56%-29.34%EVOKEvoke Pharma+29.20%+5.87%+73.38%+51.78%-3.90%GLUCGlucose Health+0.52%+8.72%+3.92%+13.43%-69.95%GTBPGT Biopharma-2.69%-12.14%-41.61%-22.32%-30.65%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCVSICV Sciences0.1166 of 5 stars0.03.00.00.00.60.00.0EVOKEvoke Pharma0.2678 of 5 stars0.02.00.00.01.70.00.6GLUCGlucose HealthN/AN/AN/AN/AN/AN/AN/AN/AGTBPGT Biopharma2.0255 of 5 stars3.84.00.00.00.00.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVSICV Sciences 0.00N/AN/AN/AEVOKEvoke Pharma 0.00N/AN/AN/AGLUCGlucose Health 0.00N/AN/AN/AGTBPGT Biopharma 3.50Strong Buy$11.00507.73% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVSICV Sciences$15.70M0.43N/AN/A$0.01 per share3.66EVOKEvoke Pharma$10.25M0.68N/AN/A$4.74 per share0.99GLUCGlucose Health$380K4.86N/AN/AN/A∞GTBPGT BiopharmaN/AN/AN/AN/A($0.75) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVSICV Sciences-$2.39MN/A0.00∞N/A-12.25%-89.43%-22.75%N/AEVOKEvoke Pharma-$5.35M-$2.87N/A∞N/A-43.80%-101.91%-33.75%8/12/2025 (Estimated)GLUCGlucose Health-$320K-$0.03N/A∞N/A-82.29%N/AN/AN/AGTBPGT Biopharma-$13.16M-$5.69N/AN/AN/AN/A-1,033.08%-223.20%8/13/2025 (Estimated)Latest GLUC, GTBP, EVOK, and CVSI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025GTBPGT Biopharma-$0.68N/AN/AN/AN/AN/A8/12/2025Q2 2025EVOKEvoke Pharma-$0.30N/AN/AN/A$3.80 millionN/A5/15/2025Q1 2025GTBPGT Biopharma-$0.64-$0.76-$0.12-$0.33N/AN/A5/12/2025Q1 2025EVOKEvoke Pharma-$0.33-$0.51-$0.18-$0.51$3.32 million$3.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCVSICV SciencesN/AN/AN/AN/AN/AEVOKEvoke PharmaN/AN/AN/AN/AN/AGLUCGlucose HealthN/AN/AN/AN/AN/AGTBPGT BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVSICV Sciences0.261.140.30EVOKEvoke PharmaN/A1.551.50GLUCGlucose HealthN/AN/AN/AGTBPGT BiopharmaN/A0.730.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVSICV SciencesN/AEVOKEvoke PharmaN/AGLUCGlucose HealthN/AGTBPGT Biopharma8.15%Insider OwnershipCompanyInsider OwnershipCVSICV Sciences3.80%EVOKEvoke Pharma2.29%GLUCGlucose HealthN/AGTBPGT Biopharma3.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVSICV Sciences70184.79 million177.77 millionNot OptionableEVOKEvoke Pharma41.49 million1.46 millionNot OptionableGLUCGlucose Health147,00017.41 millionN/ANot OptionableGTBPGT Biopharma83.27 million3.16 millionNo DataGLUC, GTBP, EVOK, and CVSI HeadlinesRecent News About These CompaniesGT Biopharma (NASDAQ:GTBP) Raised to "Sell" at Wall Street ZenJuly 28, 2025 | americanbankingnews.comGT Biopharma, Inc. (GTBP) - Yahoo FinanceJune 29, 2025 | finance.yahoo.comGTBP GT Biopharma, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comGT Biopharma, Inc. Appoints David C. Mun-Gavin to Board of DirectorsJune 15, 2025 | nasdaq.comGT Biopharma Appoints New Member to its Board of DirectorsJune 13, 2025 | globenewswire.comStocks in play: GT Biopharma, Inc.May 19, 2025 | ca.finance.yahoo.comThis Natural Killer Treatment Could Help Transform How Cancer is TreatedMay 19, 2025 | baystreet.caGT Biopharma, Inc. Advances to Cohort 2 in Phase 1 Trial of GTB-3650 Following Successful Safety Review of Cohort 1May 19, 2025 | quiverquant.comQGT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation SignalsMay 19, 2025 | globenewswire.comGT Biopharma Inc.May 18, 2025 | marketwatch.comGT Biopharma appoints new board memberMay 16, 2025 | investing.comGT Biopharma adds Hilary Kramer to Board of DirectorsMay 15, 2025 | investing.comGT Biopharma announces private placement dealMay 14, 2025 | investing.comGT Biopharma Appoints New Member to its Board of DirectorsMay 14, 2025 | globenewswire.comGT Biopharma Issues Warrant to Cytovance for Services RenderedApril 6, 2025 | investing.comGT Biopharma files to sell 625,283 shares of common stock for holdersMarch 7, 2025 | markets.businessinsider.comGT Biopharma to Participate in the 10th Anniversary of the Innate Killer SummitMarch 4, 2025 | markets.businessinsider.comGT Biopharma Retail Chatter Soars Most Among Biotechs After Financing Strategy TweakFebruary 26, 2025 | msn.comGT Biopharma, Inc. Announces Exercise of Warrants for Common Stock, Anticipating $0.7 Million in Gross ProceedsFebruary 25, 2025 | quiverquant.comQGT Biopharma Announces Exercise of WarrantsFebruary 25, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGLUC, GTBP, EVOK, and CVSI Company DescriptionsCV Sciences OTCMKTS:CVSI$0.04 +0.00 (+1.67%) As of 08/1/2025 03:56 PM EasternCV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The company offers its products under the PlusCBD, ProCBD, HappyLane, CVAcute, CVDefense, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, elect distributors, brick and mortar retailers, and select e-tailers. It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.Evoke Pharma NASDAQ:EVOK$4.69 +1.06 (+29.20%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$4.70 +0.01 (+0.32%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.Glucose Health OTCMKTS:GLUC$0.11 +0.00 (+0.47%) As of 08/1/2025 03:53 PM EasternGlucose Health, Inc. engages in the formulation, manufacturing, marketing, and distribution of soluble fiber infused nutritional beverages. It offers soluble fiber infused powdered iced tea, and flavored drink mixes for pre-diabetic and diabetic persons under the GLUCODOWN brand in North America. The company was formerly known as Bio-Solutions Corp. and changed its name to Glucose Health, Inc. in November 2014. Glucose Health, Inc. was incorporated in 2007 and is based in Bentonville, Arkansas.GT Biopharma NASDAQ:GTBP$1.81 -0.05 (-2.69%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.86 +0.05 (+2.76%) As of 08/1/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
